Clinical Trials Browser

Choroid Plexus Carcinoma, Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Cerebellar Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Nervous System Diseases, Nervous System Neoplasms, Oligodendroglioma, Virus Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor

NCT05355701 2026-05-14

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

267 enrolled

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Phase 1 Active not recruiting

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT02192359 2026-05-11

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Phase 1 Active not recruiting

18 enrolled 16 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT06964737 2026-05-08

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Phase 1 Recruiting

30 enrolled

CNS

Glioma

NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Phase 1 Active not recruiting

83 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT05565118 2026-05-07

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

Phase 1 Recruiting

10 enrolled

CNS

Glioblastoma, Glioma

NCT05293197 2026-05-06

SONOKID

Phase 1 Recruiting

24 enrolled

CNS

Brain Neoplasms, Glioma, Neoplasms, Germ Cell and Embryonal

NCT05835687 2026-05-05

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Phase 1 Recruiting

48 enrolled

CNS

Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Central Nervous System Neoplasms, Rhabdoid Tumor

NCT07076498 2026-05-05

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

Phase 1 Recruiting

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Clinical Trials

Peds IMPACT

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Concurrent Azeliragon With Craniospinal Irradiation

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

SONOKID

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation